NOT-OD-23-137: Notice of Change to RFA-OD-23-050: Emergency Award: Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21 Clinical Trial Not Allowed)

Notice of Change to RFA-OD-23-050: Emergency Award: Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21 Clinical Trial Not Allowed)

Notice Number:

NOT-OD-23-137

Key Dates

Release Date:

June 1, 2023

Related Announcements

May 2, 2023 - Emergency Award: Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21 Clinical Trial Not Allowed). See NOT-OD-23-050.

Issued by

Office of The Director, National Institutes of Health (OD)

Purpose

The purpose of this notice is to inform potential applicants of corrections to the “Key Dates” section, “Review and Award Cycles” table of RFA-OD-23-050: Emergency Award: Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21 Clinical Trial Not Allowed).

RFA-OD-23-050 states that applications will undergo Advisory Council Review in October 2023. Applications submitted in response to RFA-OD-23-050 will not undergo Advisory Council review. Secondary review will be conducted by the RADx-UP Governance and RADx Executive Committees as stated in “Section V. Application Review Information, 2. Review and Selection Process.”

“Key Dates” section, “Review and Award Cycles” table currently reads:

Advisory Council Review: October 2023

“Key Dates” section, “Review and Award Cycles” table modified to read:

Advisory Council Review: Not applicable

These changes will go into effect as of the publication date of this announcement.

Inquiries

Please direct all inquiries to:

Email: [email protected]